共 50 条
Intramyocardial, Autologous CD34+Cell Therapy for Refractory Angina
被引:376
|作者:
Losordo, Douglas W.
[1
]
Henry, Timothy D.
[2
]
Davidson, Charles
Lee, Joon Sup
[3
]
Costa, Marco A.
[4
]
Bass, Theodore
[5
]
Mendelsohn, Farrell
[6
]
Fortuin, F. David
[7
]
Pepine, Carl J.
[8
]
Traverse, Jay H.
[2
]
Amrani, David
[9
]
Ewenstein, Bruce M.
[9
]
Riedel, Norbert
[9
]
Story, Kenneth
[9
]
Barker, Kerry
[9
]
Povsic, Thomas J.
[10
]
Harrington, Robert A.
[10
]
Schatz, Richard A.
[11
]
机构:
[1] Northwestern Univ, NW Mem Hosp, Program Cardiovasc Regenerat Med, Div Cardiol, Chicago, IL 60611 USA
[2] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[5] Shands Jacksonville Med Ctr, Jacksonville, FL USA
[6] Ctr Therapeut Angiogenesis, Birmingham, AL USA
[7] Mayo Clin, Scottsdale, AZ USA
[8] Univ Florida, Gainesville, FL USA
[9] Baxter Healthcare Corp, Deerfield, IL 60015 USA
[10] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[11] Scripps Green Hosp, La Jolla, CA USA
关键词:
angiogenesis;
endothelial progenitor cells (EPC) myocardial ischemia;
myocardial regeneration;
stem cells;
PERCUTANEOUS CORONARY INTERVENTION;
MYOCARDIAL-INFARCTION;
UNIVERSAL DEFINITION;
CELL TRANSPLANTATION;
RANDOMIZED-TRIAL;
RESEARCH ISSUES;
ARTERY-DISEASE;
HEART-DISEASE;
DOUBLE-BLIND;
ANGIOGENESIS;
D O I:
10.1161/CIRCRESAHA.111.245993
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Rationale: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function. Objective: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. Methods and Results: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1X10(5) or 5X10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8 +/- 1.1 versus 10.9 +/- 1.2, P=0.020) and 12 months (6.3 +/- 1.2 versus 11.0 +/- 1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139 +/- 151 versus 69 +/- 122 seconds, P=0.014; 12 months: 140 +/- 171 versus 58 +/- 146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients. Conclusions: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies. (Circ Res. 2011;109:428-436.)
引用
收藏
页码:428 / 436
页数:9
相关论文